Teiji Takeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Teiji Takeda has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Kiyoshi Hashizume
Department of Aging Medicine and Geriatrics, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine
6 shared publicationsKazuo Ichikawa
Department of Aging Medicine and Geriatrics, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
4 shared publicationsSatoru Suzuki
4 shared publicationsTakahide Miyamoto
Department of Aging Medicine and Geriatrics (T.T., H.I., T.M., S.S., T.K., M.H., K.H.), Shinshu University, Graduate School, Matsumoto, Nagano 390-8621, Japan
3 shared publicationsHidehumi Inaba
Department of Aging Medicine and Geriatrics (T.T., H.I., T.M., S.S., T.K., M.H., K.H.), Shinshu University, Graduate School, Matsumoto, Nagano 390-8621, Japan
2 shared publicationsMasanori Yamazaki
Thyroid Study Unit (M.Y., L.D.G.), Department of Medicine, University of Chicago, Chicago, Illinois 60637
2 shared publications
Latest Publications
- 28 September 2006
- p. 337-42
[Multiple endocrine neoplasia type IIa (MEN2A)].
- 1 March 2006
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 6 (1) , 1-6
Endocrinological aspects of aging: Adaptation to and acceleration of aging by the endocrine system
- 1 March 2006
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 6 (1) , 1-6
Endocrinological aspects of aging: Adaptation to and acceleration of aging by the endocrine system
- Open Access
- 1 August 2003
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 88 (8) , 3531-3538
Tumor-Specific Gene Therapy for Undifferentiated Thyroid Carcinoma Utilizing the Telomerase Reverse Transcriptase Promoter
A tumor-specific targeting system for cancer gene therapy was studied using the human telomerase reverse transcriptase (hTERT) promoter. Telomerase activity is increased in most tumors but not detected in most normal cells. We developed the recombinant adenovirus, carrying human herpes simplex virus thymidine kinase gene under the control of the hTERT promoter (AdhTERTtk) to obtain restricted expression of a suicide gene only in tumor cells. We found that transcriptional activity of hTERT was 2- to 9-fold higher in undifferentiated thyroid carcinoma cell lines than that of the Simian virus 40 promoter in transient transfection assay. Undifferentiated thyroid carcinoma cell lines were infected with AdhTERTtk, and sensitivity to ganciclovir (GCV) was analyzed. Cell viability was decreased in a GCV dose-dependent manner after treatment with AdhTERTtk/GCV. The cell-killing ability of AdhTERTtk in all thyroid or nonthyroid carcinoma cell lines tested was similar to AdCMVtk, which carries herpes simplex virus thymidine kinase gene driven by the cytomegalovirus promoter. However, normal cell lines were largely unaffected by AdhTERTtk/GCV, whereas these cells were also sensitive to GCV after infection with AdCMVtk. A xenograft model was established by transplanting human differentiated or undifferentiated thyroid carcinoma cells into Balb-C nude mice. The injections of AdhTERTtk into tumors and ip administration of GCV showed significant inhibition of tumor growth, similar to AdCMVtk/GCV treatment. Systemic administrations of adenovirus and GCV to normal rats demonstrated remarkable increase of serum liver transaminase levels and severe hepatic damages in pathological examinations in AdCMVtk-injected rats but not in the AdhTERTtk group. These results indicate that the AdhTERTtk/GCV system is a promising therapy for undifferentiated thyroid carcinoma, which is one of the most malignant tumors, without damage to normal tissues.
- 1 August 2003
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 88 (8) , 3531-3538
Open AccessTumor-Specific Gene Therapy for Undifferentiated Thyroid Carcinoma Utilizing the Telomerase Reverse Transcriptase Promoter
A tumor-specific targeting system for cancer gene therapy was studied using the human telomerase reverse transcriptase (hTERT) promoter. Telomerase activity is increased in most tumors but not detected in most normal cells. We developed the recombinant adenovirus, carrying human herpes simplex virus thymidine kinase gene under the control of the hTERT promoter (AdhTERTtk) to obtain restricted expression of a suicide gene only in tumor cells. We found that transcriptional activity of hTERT was 2- to 9-fold higher in undifferentiated thyroid carcinoma cell lines than that of the Simian virus 40 promoter in transient transfection assay. Undifferentiated thyroid carcinoma cell lines were infected with AdhTERTtk, and sensitivity to ganciclovir (GCV) was analyzed. Cell viability was decreased in a GCV dose-dependent manner after treatment with AdhTERTtk/GCV. The cell-killing ability of AdhTERTtk in all thyroid or nonthyroid carcinoma cell lines tested was similar to AdCMVtk, which carries herpes simplex virus thymidine kinase gene driven by the cytomegalovirus promoter. However, normal cell lines were largely unaffected by AdhTERTtk/GCV, whereas these cells were also sensitive to GCV after infection with AdCMVtk. A xenograft model was established by transplanting human differentiated or undifferentiated thyroid carcinoma cells into Balb-C nude mice. The injections of AdhTERTtk into tumors and ip administration of GCV showed significant inhibition of tumor growth, similar to AdCMVtk/GCV treatment. Systemic administrations of adenovirus and GCV to normal rats demonstrated remarkable increase of serum liver transaminase levels and severe hepatic damages in pathological examinations in AdCMVtk-injected rats but not in the AdhTERTtk group. These results indicate that the AdhTERTtk/GCV system is a promising therapy for undifferentiated thyroid carcinoma, which is one of the most malignant tumors, without damage to normal tissues.
- 11 September 2002
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 9 (10) , 864-874
A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas
Recombinant adenoviruses, carrying herpes simplex virus thymidine kinase (HSVtk) genes, were developed to evaluate the possibility of tissue-specific gene therapy for thyroid carcinomas. The HSVtk gene was driven by a minimal thyroglobulin (TG) promoter (AdTGtk) and a tandemly repeated minimal TG promoter (Ad2 x TGtk) to obtain thyroid-specific cell killing ability. The transduction of HSVtk genes by infection with Ad2 x TGtk followed by ganciclovir (GCV) treatment showed more powerful cytotoxicity for TG-producing FRTL5 cells, a rat normal thyroid cell line, and FTC-133 cells, a human follicular thyroid carcinoma cell line, than when infected with AdTGtk in vitro. The cell killing ability of Ad2 x TGtk was 10- to 30-fold higher than that of AdTGtk and similar to that of AdCMVtk, which carries HSVtk under the control of CMV promoter. Whereas after treatment with adenovirus/GCV to non-TG-producing cell lines (undifferentiated thyroid carcinoma cell lines and carcinoma cell lines from other tissues), Ad2 x TGtk and AdTGtk needed more than 100-fold concentrated GCV to reach IC(50) compared to AdCMVtk. We confirmed the enhanced efficacy of Ad2 x TGtk for tissue-specific cytotoxicity in vivo. After adenovirus/GCV treatment for FTC-133 tumor-bearing nude mice, Ad2 x TGtk enhanced tumor growth inhibition and survival rates compared to AdTGtk. Tumor growth inhibition and survival rates by Ad2 x TGtk were similar to that by AdCMVtk. Moreover, any toxic effect for rat normal tissues was not revealed after intravenous injections with Ad2 x TGtk and intraperitoneal administrations with GCV in vivo, whereas severe liver damages were observed after treatment with AdCMVtk/GCV. These data indicate a beneficial effect of Ad2 x TGtk for tissue-specific gene therapy for TG-producing thyroid carcinomas without toxicity for normal tissues.
- 11 September 2002
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 9 (10) , 864-874
A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas
Recombinant adenoviruses, carrying herpes simplex virus thymidine kinase (HSVtk) genes, were developed to evaluate the possibility of tissue-specific gene therapy for thyroid carcinomas. The HSVtk gene was driven by a minimal thyroglobulin (TG) promoter (AdTGtk) and a tandemly repeated minimal TG promoter (Ad2 x TGtk) to obtain thyroid-specific cell killing ability. The transduction of HSVtk genes by infection with Ad2 x TGtk followed by ganciclovir (GCV) treatment showed more powerful cytotoxicity for TG-producing FRTL5 cells, a rat normal thyroid cell line, and FTC-133 cells, a human follicular thyroid carcinoma cell line, than when infected with AdTGtk in vitro. The cell killing ability of Ad2 x TGtk was 10- to 30-fold higher than that of AdTGtk and similar to that of AdCMVtk, which carries HSVtk under the control of CMV promoter. Whereas after treatment with adenovirus/GCV to non-TG-producing cell lines (undifferentiated thyroid carcinoma cell lines and carcinoma cell lines from other tissues), Ad2 x TGtk and AdTGtk needed more than 100-fold concentrated GCV to reach IC(50) compared to AdCMVtk. We confirmed the enhanced efficacy of Ad2 x TGtk for tissue-specific cytotoxicity in vivo. After adenovirus/GCV treatment for FTC-133 tumor-bearing nude mice, Ad2 x TGtk enhanced tumor growth inhibition and survival rates compared to AdTGtk. Tumor growth inhibition and survival rates by Ad2 x TGtk were similar to that by AdCMVtk. Moreover, any toxic effect for rat normal tissues was not revealed after intravenous injections with Ad2 x TGtk and intraperitoneal administrations with GCV in vivo, whereas severe liver damages were observed after treatment with AdCMVtk/GCV. These data indicate a beneficial effect of Ad2 x TGtk for tissue-specific gene therapy for TG-producing thyroid carcinomas without toxicity for normal tissues.
- 1 January 1993
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 40 (4) , 399-404
Induction of Cytosolic Triiodo-L-Thyronine (T3) Binding Protein (CTBP) by T3 in Primary Cultured Rat Hepatocytes.
Cytosolic 3, 5, 3'-triiodo-L-thyronine (T3)-binding protein (CTBP) plays an important role in the regulation of intracellular T3 translocation from cytoplasm to the nuclear T3 receptor. We examined whether the CTBP activity could be induced by T3 or not in cultured hepatocytes prepared from thyroidectomized rats. CTBP activity was not detected in primary cultured hepatocytes from thyroidectomized rats. However, the protein was induced by the addition of T3 to the culture medium. The increase in the activity of CTBP was time dependent and the maximal level was obtained by 48 h in the presence of 300 nM T3. CTBP activity was also increased by retinol (35 microM) or by 1,25-(OH)2-vitamin D3 (10 nM). On the other hand, the activity of malic enzyme (ME) was induced by the addition of T3 to the culture medium. The maximal activity of ME was obtained by 48 h in the presence of 300 nM T3. The increase in ME activity was also induced by retinol or 1,25-(OH)2-vitamin D3. These results suggested that not only ME activity but also CTBP activity is induced by T3. Further, retinol and vitamin D3 have similar effects on the induction of CTBP activity and ME activity.
- 1 January 1993
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 40 (4) , 399-404
Induction of Cytosolic Triiodo-L-Thyronine (T3) Binding Protein (CTBP) by T3 in Primary Cultured Rat Hepatocytes.
Cytosolic 3, 5, 3'-triiodo-L-thyronine (T3)-binding protein (CTBP) plays an important role in the regulation of intracellular T3 translocation from cytoplasm to the nuclear T3 receptor. We examined whether the CTBP activity could be induced by T3 or not in cultured hepatocytes prepared from thyroidectomized rats. CTBP activity was not detected in primary cultured hepatocytes from thyroidectomized rats. However, the protein was induced by the addition of T3 to the culture medium. The increase in the activity of CTBP was time dependent and the maximal level was obtained by 48 h in the presence of 300 nM T3. CTBP activity was also increased by retinol (35 microM) or by 1,25-(OH)2-vitamin D3 (10 nM). On the other hand, the activity of malic enzyme (ME) was induced by the addition of T3 to the culture medium. The maximal activity of ME was obtained by 48 h in the presence of 300 nM T3. The increase in ME activity was also induced by retinol or 1,25-(OH)2-vitamin D3. These results suggested that not only ME activity but also CTBP activity is induced by T3. Further, retinol and vitamin D3 have similar effects on the induction of CTBP activity and ME activity.
- 1 January 1991
- Published by Japanese Society of Internal Medicine in Japanese Journal of Medicine
- Vol. 30 (4) , 351-353
A Case of Sarcoidosis Associated with Bronchial Asthma.
A 54-year-old woman was treated for bronchial asthma for 14 yr. In March of 1989, chest roentgenography and computed tomography (CT) revealed development of bilateral pulmonary hilar lymph node enlargement. Positive 67Ga uptake was observed in bilateral pulmonary hili. Although levels of serum angiotensin converting enzyme (ACE) and lysozyme were within normal range, biopsy specimen of scalene lymph nodes showed noncaseating epitheloid-cell granuloma, leading to the diagnosis of sarcoidosis. Steroid therapy ameliorated both sarcoidosis and bronchial asthma. Although the association of sarcoidosis and bronchial asthma is uncommon, there may be an etiological relationship between them.
- 1 January 1991
- Published by Japanese Society of Internal Medicine in Japanese Journal of Medicine
- Vol. 30 (4) , 351-353
A Case of Sarcoidosis Associated with Bronchial Asthma.
A 54-year-old woman was treated for bronchial asthma for 14 yr. In March of 1989, chest roentgenography and computed tomography (CT) revealed development of bilateral pulmonary hilar lymph node enlargement. Positive 67Ga uptake was observed in bilateral pulmonary hili. Although levels of serum angiotensin converting enzyme (ACE) and lysozyme were within normal range, biopsy specimen of scalene lymph nodes showed noncaseating epitheloid-cell granuloma, leading to the diagnosis of sarcoidosis. Steroid therapy ameliorated both sarcoidosis and bronchial asthma. Although the association of sarcoidosis and bronchial asthma is uncommon, there may be an etiological relationship between them.